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Abstract
Background: Histone deacetylase inhibitors (HDACi) suppress cytokine production in immune and stromal cells of
patients with rheumatoid arthritis (RA). Here, we investigated the effects of the HDACi givinostat (ITF2357) on the
transcriptional and post-transcriptional regulation of inflammatory markers in RA fibroblast-like synoviocytes (FLS).
Methods: The effects of ITF2357 on the expression and messenger RNA (mRNA) stability of IL-1β-inducible genes in
FLS were analyzed using array-based qPCR and Luminex. The expression of primary and mature cytokine transcripts,
the mRNA levels of tristetraprolin (TTP, or ZFP36) and other AU-rich element binding proteins (ARE-BP) and the
cytokine profile of fibroblasts derived from ZFP36+/+ and ZFP36−/− mice was measured by qPCR. ARE-BP silencing
was performed by small interfering RNA (siRNA)-mediated knockdown, and TTP post-translational modifications
were analyzed by immunoblotting.
Results: ITF2357 reduced the expression of 85% of the analyzed IL-1β-inducible transcripts, including cytokines
(IL6, IL8), chemokines (CXCL2, CXCL5, CXCL6, CXCL10), matrix-degrading enzymes (MMP1, ADAMTS1) and other
inflammatory mediators. Analyses of mRNA stability demonstrated that ITF2357 accelerates IL6, IL8, PTGS2 and CXCL2
mRNA degradation, a phenomenon associated with the enhanced transcription of TTP, but not other ARE-BP, and
the altered post-translational status of TTP protein. TTP knockdown potentiated cytokine production in RA FLS and
murine fibroblasts, which in the latter case was insensitive to inhibition by ITF2357 treatment.
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Conclusions: Our study identifies that regulation of cytokine mRNA stability is a predominant mechanism
underlying ITF2357 anti-inflammatory properties, occurring via regulation of TTP. These results highlight the
therapeutic potential of ITF2357 in the treatment of RA.
Keywords: Rheumatoid arthritis, Fibroblast-like synoviocytes, Inflammation, mRNA stability, Tristetraprolin, Histone
deacetylase inhibitor, ITF2357
Background
Rheumatoid arthritis (RA) is a chronic immune-mediated
inflammatory disease, characterized by the excessive acti-
vation of the immune system and the uncontrolled pro-
duction of cytokines and other inflammatory mediators in
synovial joints. Cytokines such as tumor necrosis factor
(TNF) and interleukin (IL)-1β produced by macrophages
and lymphocytes infiltrating the synovial tissue lead to the
abnormal activation of fibroblast-like synoviocytes (FLS),
which in turn causes bone and cartilage deterioration [1].
Regulation of inflammatory cytokines occurs at multiple
levels and results from the intricate modulation of epigen-
etic regulatory mechanisms, activation of intracellular
signaling pathways, control of messenger RNA (mRNA)
stability and protein translation. The correct regulation of
mRNA decay is critical for immune homeostasis, as it al-
lows cells to quickly adjust the expression of inflammatory
mediators, the overproduction of which could adversely
affect the organism [2]. Conditions that interfere with
stability of mRNA are associated with diverse diseases,
including chronic inflammation and cancer [3].
Adenosine uridine (AU)-rich elements (AREs) represent
one of the largest and most important groups of cis-acting
mRNA stability determinants. AREs allow the recruitment
of trans-acting ARE binding proteins (ARE-BP), which in
turn mediate mRNA degradation [4]. Several human
ARE-BP have been identified, such as tristetraprolin (TTP,
or ZFP36), TTP family members BRF1 (ZFP36L1) and
BRF2 (ZFP36L2), AU-rich binding factor-1 (AUF1, or
HNRNPD), KH-type splicing regulatory protein (KHSRP),
and Hu antigen R (HuR, or ELAVL1). The majority of
ARE-BP promote the recruitment of ARE-containing
mRNAs to the exosomes for eventual degradation,
although some, such as HuR and Hu family members, act
as mRNA stabilizing factors [5].
The expression of several ARE-BP was found to be
dysregulated in RA, and their silencing shown to affect
key regulatory mechanisms in arthritis pathogenesis,
both in vitro and in vivo [6–10]. To date, TTP is the
ARE-BP that has been best characterized and associated
with RA development and disease progression [11, 12].
TTP expression is altered in patients with synovium
affected by RA [11] and TTP-deficient mice display a
severe inflammatory phenotype that includes synovial
pannus formation and erosive arthritis [10]. Remarkably,
overexpression of endogenous TTP or mutations at TTP
phosphorylation sites protect mice in experimental
models of arthritis [11, 13].
Growing interest in the modulation of ARE-BP in RA
pathology has thus promoted the search for novel inhibitory
compounds that can reverse the aberrant expression and
function of ARE-BP. Inhibitors of the mitogen-activated
protein kinase (MAPK) p38, a critical regulator of the phos-
phorylation status and activity of multiple ARE-BP, have
been extensively used to dampen uncontrolled production
of pro-inflammatory cytokines resulting from dysregulated
mRNA decay [14]. However, p38 inhibitors are currently
not approved for RA treatment due to molecule-related
adverse events, such as cutaneous toxicity, and limited clin-
ical efficacy [15, 16]. HDACi represent a novel class of small
molecule drugs that have shown promising results in vitro
and in vivo in models of RA and immune-related diseases
[17, 18] and have demonstrated initial clinical efficacy in the
treatment of systemic-onset juvenile idiopathic arthritis
[19]. Although the primary mechanism of action of HDACi
is proposed to rely on the regulation of chromatin opening
and transcription, studies have reported that HDACi can
impair cytokine mRNA expression despite favoring their
transcriptional activation [20, 21]. We previously reported
that pan-specific HDACi ITF2357 (Givinostat) and trichos-
tatin A (TSA) prevented IL-6 production in RA FLS and
macrophages by promoting accelerated degradation of IL6
mRNA [22].
In this study, we aimed to dissect the transcriptional
and post-transcriptional regulation of cytokine mRNA
expression by ITF2357, and to identify whether, and
through which mechanisms, HDACi can restore the bal-
ance in mRNA-stability mechanisms that are deregulated
in RA.
Methods
Patient material and FLS isolation
FLS were derived from synovial tissue specimens
obtained from patients with RA by needle arthroscopy,
as previously described [23], cultured in medium supple-
mented with 10% fetal bovine serum (FBS, Invitrogen),
and used between passages 4 and 10. All patients
fulfilled the criteria for the classification of RA and had
active disease including clinical arthritis of the joint from
which the synovial biopsies were obtained [24].
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FLS treatment and stimulation
FLS were cultured overnight in Dulbecco’s Modified
Eagle Medium (DMEM, Life Technologies) containing
1% FBS prior to incubation with cytokines. Cells were
pre-incubated for 30 min with either 250 nM pan-HDAC
inhibitor ITF2357 (Italfarmaco) or 5 μM p38 inhibitor
(SB202190, Sigma) and stimulated with 1 ng/ml IL-1β
(R&D Systems). Information about the specificity of the
HDACi is published [25].
RNA extraction and gene expression profiling
RNeasy Micro Kit (Qiagen) was used for RNA extraction.
Quantity and purity of RNA was assessed using a Nano-
drop spectrophotometer (Nanodrop Technologies). RNA
was reverse-transcribed using a First-Strand complemen-
tary DNA (cDNA) synthesis kit (Thermo Scientific) and
quantitative (q)PCR was performed using Sybr Select PCR
Master Mix (Applied Biosystems). For qPCR array ana-
lysis, RNA was reverse-transcribed using an RT2 HT First
Strand Kit (Qiagen), cDNA was mixed with Sybr Green
qPCR Master Mix (Qiagen) and expression of 83 genes
involved in FLS activation was analyzed using RT2 Profiler
customized qPCRarrays. qPCR reactions were performed
on a StepOnePlus Real-Time PCR System (Applied
Biosystems) and relative mRNA expression was calculated
using StepOne Software V.2.1 (Applied Biosystems).
Sequences of the primers used are listed in Additional file 4.
The ratio between the gene of interest and the expression
of human GAPDH or murine ACTB housekeeping genes,
or the expression of five housekeeping genes (B2M,
HPRT1, RPL13A, GAPDH and ACTB) was calculated for
qPCR and qPCR arrays, respectively.
Protein extraction and immunoblotting
FLS were lysed in Laemmli’s buffer and protein content
was quantified with a BCA Protein Assay Kit (Pierce).
Equivalent amounts of total protein lysate were then
mixed with loading buffer and boiled at 95 °C for 5 min.
Proteins were resolved by electrophoresis on either 4–
12% Bis-Tris SDS NuPAGE gels (Invitrogen) for 1 h at
constant 200 V, or on 10% SDS-PAGE gels for 5 h at
constant 70 V for better separation of immunoreactive
bands ranging between 26 and 55 kDa. Gels were trans-
ferred to polyvinylidene difluoride (PVDF) membranes
(Bio-Rad Laboratories), membranes were blocked in
Tris-buffered saline (pH 8.0) containing 0.05% Tween-20
(Bio-Rad) and 4% milk (Bio-Rad), washed and probed
overnight at 4 °C with antibodies recognizing TTP (Cell
Signaling), histone 3 (H3) (Cell Signaling) or tubulin
(Sigma-Aldrich). After washing, membranes were incu-
bated with horseradish peroxidase (HRP)-conjugated
swine anti-rabbit or goat anti-mouse immunoglobulin
secondary antibody (Dako), and protein visualization
was performed using a ChemiDoc MP system (Bio-Rad).
Luminex assay
RA FLS were left unstimulated or were treated with
250 nM ITF2357 for 30 min prior to stimulation with
1 ng/ml IL-1β for 24 h. Supernatants were harvested
and IL-8, matrix metalloproteinase (MMP)-3, CXCL-10,
CXCL-5 and CXCL-6 protein secretion determined by
Luminex (BioRad) according to the manufacturer’s
instructions at the core facility of the Academic Medical
Center (AMC).
Analysis of mRNA stability
FLS were left unstimulated or were treated with 250 nM
ITF2357 for 30 min prior to stimulation with 1 ng/ml
IL-1β. After 2 h of stimulation culture medium was
discarded, cells were washed and fresh medium containing
10 μg/ml actinomycin D (ActD) (Sigma-Aldrich) was
added. Cells were then harvested at 0, 2 and 5 h following
the addition of ActD, RNA was isolated, and the rates of
mRNA degradation in the presence or absence of HDACi
assessed using a customized RT2 Profiler™ PCR Array set
(SABiosciences) as described above. Transcripts displaying
at least 1.5-fold change in the rate of degradation, com-
pared to IL-1β-stimulated controls were analyzed.
Lambda phosphatase treatment
FLS were lysed in 1 × NEBuffer (New England Biolabs)
supplemented with 1 mM MnCl2. Cell lysate was
incubated on ice for 20 min, spun down, and supernatant
was collected and incubated with 10,000 U/ml lambda (λ)
phosphatase (New England Biolabs) at 30 °C for 30 min.
Protein lysate was added to loading buffer and boiled at
95 °C for 5 min, and further processed for immunoblot-
ting as described above.
siRNA transfection
RA FLS were transfected using DharmaFECT1 (Thermo
Scientific). The day before transfection, cells were incubated
with DMEM containing 10% FBS which was then replaced
with OPTI-MEM serum-reduced medium. AUF1, BRF1,
BRF2, KHSRP, HuR and TTP specific small interfering
RNA (siRNA) (20 nM) and control non-targeting siRNA
(20 nM), (Thermo Scientific) were mixed with Dharma-
FECT1 and incubated for 20 min at room temperature
prior to transfection; 24 h after transfection, medium was
replaced with DMEM containing 10% FBS and this was left
for another 24 h.
TTP wild-type and knockout MEF
Mouse embryonic fibroblasts (MEF) were derived from
littermate E14.5 Zfp36 (TTP) +/+ and Zfp36 (TTP)− /−
embryos, as previously described [10]. Zfp36−/− mice were
generated by inserting a targeting vector containing a
neomycin resistance gene (neo) in the TTP protein-coding
region, which generated multiple stop codons and
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precluded synthesis of the functional protein. MEFs were
maintained in medium containing 10% FBS, 100 U/ml
penicillin, 100 μg/ml streptomycin, and 2mM L-glutamine.
Zfp36−/− cells were regularly maintained for one passage
in feeding medium containing 0.3 mg/ml of the selection
antibiotic Geneticin (G418, Thermo Fisher Scientific).
Statistical analysis
Data are presented as mean ± SEM unless otherwise indi-
cated. One-way analysis of variance (ANOVA) was used
for analyzing sets of data requiring multiple comparisons.
Wilcoxon matched pairs test and the ratio t test was used
for all other paired comparisons. Data were analyzed using
GraphPad software 7 with p values < 0.05 considered
statistically significant.
Results
ITF2357 rapidly suppresses the expression of IL-1β-
induced inflammatory genes
We and others have shown that the pan-HDACi ITF2357
is a potent suppressor of genes regulating inflammatory ac-
tivation, adhesion, angiogenesis, cell survival and extracellu-
lar matrix degradation [25–27]. Specifically, by screening a
broad subset of genes relevant to disease pathology in RA,
we found that treatment with ITF2357 reduced the expres-
sion of the majority of genes responsive to IL-1β stimula-
tion in RA FLS [26]. To gain more insight into temporal
changes in gene expression in the presence of the HDACi,
we analyzed the kinetics of mRNA regulation of 83 selected
genes using customized qPCR arrays (Fig. 1a and
Additional file 1). ITF2357 reduced the expression of 85%
of the analyzed transcripts, regardless of the kinetics of
gene induction after IL-1β stimulation. As earlier shown for
IL6 [22], the reduction observed in cytokine mRNA accu-
mulation after ITF2357 treatment corresponded to changes
at the protein level (Fig. 1b).
Reduced expression of a subset of ITF2357-regulated
genes is associated with mRNA decay
In a previous study we demonstrated that both the
pan-HDACi ITF2357 and trichostatin A (TSA) acceler-
ate the mRNA decay of IL6 in RA FLS and healthy
donor macrophages [22]. To test whether this observa-
tion could be extended to other inflammatory mediators,
we analyzed mRNA stability of the genes screened in
our mRNA kinetics experiment. In addition to IL6
mRNA, the stability of other transcripts, such as IL8,
CXCL2, PTGS2, ADAMTS1, and BCL2L1, was reduced
after ITF2357 treatment (Additional file 2). In contrast,
other genes including MMP1, MMP3, CXCL5, CXCL6,
CXCL10, FoxO1 and ADAMTS1 were not affected by
ITF2357 at the post-transcriptional level, even though
their mRNA expression was reproducibly regulated by
ITF2357 (Additional files 1 and 2). Independent qPCR
assays confirmed reduced mRNA stability of IL6, IL8,
CXCL2 and PTGS2 transcripts after ITF2357 treatment
(Fig. 2a).
In order to further dissect the transcriptional and
post-transcriptional effects of ITF2357 on mRNA
expression, we quantified unspliced primary transcripts
of the genes that were either affected (IL6, IL8 and
PTGS2) or unaffected (MMP1) by ITF2357 at the level
OF mRNA decay, and compared them with their
respective mature transcripts (Fig. 2b). The difference
between primary and mature transcript expression of
IL6, IL8 and PTGS2 after 4 h treatment with ITF2357
was modest; however, it became more prominent at 8 h
and marked a pronounced reduction in the expression
of the mature transcript. Conversely, MMP1 primary
and mature transcript rates were similar. These results
confirmed that genes found unaffected by ITF2357 in
terms of mRNA decay (e.g. MMP1) are predominantly
regulated at the transcriptional level, while those desta-
bilized by ITF2357 treatment are post-transcriptionally
regulated.
ITF2357 leads to TTP transcriptional and post-
translational changes
Early studies in cancer cells indicated that HDACi modu-
late ARE-BP function [28, 29]. Therefore, we investigated
the expression of both destabilizing (TTP, AUF1, BRF1,
BRF2, KHRSP) and stabilizing (HuR) ARE-BP after short
treatment with ITF2357 in RA FLS. We found that TTP
was induced by IL-1β and further upregulated by
ITF2357. Conversely, other ARE-BP were either not
induced by IL-1β or did not exhibit a specific regulation
pattern in combination with the HDACi (Fig. 3a). We
confirmed that ITF2357 led to sustained TTP mRNA
expression at later time points (Fig. 3b), while not indu-
cing any of the other ARE-BP (data not shown). We thus
investigated whether induction of TTP mRNA expression
by ITF2357 could also derive from the enhanced stability
of the transcript. Surprisingly, ITF2357 rather acted as a
destabilizing factor of TTP mRNA (Fig. 3c), while enhan-
cing TTP primary transcript at all time points (Fig. 3d).
Following inflammatory or growth factor-driven p38
MAPK activation, TTP protein is phosphorylated on
different amino acid residues, becoming inactivated [30].
We therefore examined whether ITF2357 could also affect
TTP activity by altering its post-translational status. After
2 h IL-1β stimulation, we observed increased intensity of
an immunoreactive band (45 kDa) at the expected
mobility for TTP (Fig. 3e). A band with higher molecular
weight of approximately 47 kDa was detected after 4 h,
and confirmed by higher immunoblot resolution
(Additional file 3A), suggesting phosphorylation of the
protein [31]. ITF2357 significantly reduced the intensity of
the higher band (Fig. 3e and Additional file 3A), similarly
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to p38 MAPK inhibition (Additional file 3B). Additionally,
protein lysate treatment with λ-phosphatase reduced the
intensity of TTP band upon IL-1β stimulation but did not
further reduce TTP signal in samples treated with either
ITF2357 or p38 inhibitor (Additional file 3C). Together,
these results suggest that ITF2357 has a dual role in the
regulation of TTP, by inducing mRNA expression at the
transcriptional level, and by preventing TTP phosphoryl-
ation and subsequent inactivation.
ITF2357 suppresses cytokine production independently of
AUF1, BRF1, BRF2, KHSRP and HuR
Despite the prevalent effect of ITF2357 on TTP mRNA
induction, we could not exclude the possibility that
ITF2357 may impact other ARE-BP by different mecha-
nisms of action, e.g. by modifying their post-translational
state. To investigate whether any of the other ARE-BP
included in our study would be required for ITF2357
effects on IL6, IL8, CXCL2 or PTGS2 mRNA expression,
we performed knockdown of AUF1, BRF1, BRF2, KHSRP
and HuR in RA FLS, achieving 80–95% silencing
efficiency (Fig. 4a). We observed that knockdown of these
genes led to minor changes in cytokine gene expression
(Fig. 4b) and that ITF2357 similarly suppressed cytokine
production in both control and ARE-BP knockdown
conditions. A trend towards downregulation of IL6 and
PTGS2 mRNA expression was noticeable upon KH-type
splicing regulatory protein (KHSRP) knockdown, possibly
indicating alternative mechanisms of regulation by this
ARE-BP, which go beyond direct control of mRNA
stability [32]. Overall, these results indicate that, despite
potential post-translational modifications occurring on
other ARE-BP after ITF2357 treatment, these would not
be sufficient to mediate changes in the expression of the
inflammatory mediators considered in our study.
TTP silencing causes pro-inflammatory responses in RA
FLS and is required to prevent ITF2357-dependent IL6
suppression in murine fibroblasts
We next investigated the effects of TTP silencing on
cytokine expression in RA FLS. TTP siRNA-mediated
knockdown resulted in 50% reduction of TTP mRNA
expression (Fig. 5a, left panel), confirmed at the protein
level (Fig. 5a, right panel), which was sufficient to cause
increased cytokine expression of IL6, IL8, CXCL2 and
PTGS2 (Fig. 5b), but not MMP1 (data not shown) both
in unstimulated (IL6, IL8) and IL-1β-stimulated
conditions (IL6, IL8, PTGS2). Although not statistically
significant (p = 0.05), induction of CXCL2 after TTP
knockdown was also observed. ITF2357 still mediated
cytokine suppression in the presence or absence of TTP
(Fig. 5c), possibly because TTP silencing only reduced
the steady-state levels of TTP mRNA but was unable to
fully prevent its upregulation by ITF2357 (Fig. 5c, right
panel). In line with this hypothesis, recent studies
indicated that, even when minimal, TTP expression is
sufficient to suppress inflammatory responses [30].
Because TTP protein domains are remarkably conserved
within vertebrates, and share a common regulatory
mechanism [33, 34], we made use of fibroblasts derived
from wild-type (ZFP36+/+) and TTP knockout (ZFP36−/−)
mice [35], and stimulated them with IL-1β to mimic ex-
perimental conditions used in RA FLS. Higher expression
of IL6, CXCL2 and PTGS2 mRNA in ZFP36−/− fibroblasts
indicated that these cytokines are TTP targets, as previ-
ously described [36–38]. In addition, while in wild-type
fibroblasts IL6 mRNA expression was significantly
reduced by ITF2357, no significant suppression was
observed in ZFP36−/− fibroblasts (Fig. 5d). A similar trend
was also observed for CXCL2, while PTGS2 was not
reduced by ITF2357 in wild-type fibroblasts. Our findings
indicate that TTP is an important regulator of cytokine
mRNA expression in RA FLS, and suggest that this
ARE-BP is responsible for mediating part of the
anti-inflammatory properties of ITF2357.
Discussion
In RA and in other immune-mediated inflammatory dis-
eases (IMIDs), the excessive production and accumulation
of cytokines and chemokines contributes to the perpetu-
ation of chronic inflammation and immune responses [1].
Continuous exposure to pro-inflammatory stimuli drives
RA FLS to develop an epigenetically imprinted, aggressive
phenotype and inflammatory memory that promotes the
degradation of synovial joints [39]. Development of immu-
nomodulatory epigenetic inhibitors has emerged in recent
years. Among these, HDACi comprise a class of small
anti-inflammatory molecules that showed pre-clinical
(See figure on previous page.)
Fig. 1 ITF2357 suppresses the expression of IL-1β-responsive genes. a Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) (n = 3) were
either left untreated or were treated with ITF2357 prior to incubation with IL-1β for the indicated time. Temporal changes in mRNA accumulation
of IL-1β-inducible genes were monitored using a customized qPCR array system. Data are presented as fold changes in mRNA levels compared
to unstimulated cells in the presence or absence of ITF2357 Differences in fold changes between IL-1β and IL-1β + ITF2357 conditions, for each
time point, were analyzed by ratio t test: *p < 0.05, **p < 0.01. b RA FLS were either left untreated or were treated with ITF2357 prior to
incubation with IL-1β for 24 h. FLS supernatant was harvested and levels of IL-8, matrix metalloproteinase (MMP)-3, CXCL-10 (n = 6) CXCL-5 and
CXCL-6 (n = 5) were measured by Luminex. Protein concentrations were normalized to 100% in each experiment for samples not treated with
histone deacetylase inhibitor and expressed as the percentage of control:*p < 0.05, ***p < 0.001, ratio t test
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potential for the treatment of RA [18]. Despite extensive
research in recent years, the mode of action of these com-
pounds remains largely unknown.
Here we show that in RA FLS, pan-HDACi ITF2357
efficiently suppresses cytokine production independently
of the kinetics of gene induction by IL-1β. As we previ-
ously found that IL-6, a key cytokine contributing to RA
pathobiology, was suppressed by ITF2357 via acceleration
of IL6 mRNA decay [22], we aimed to investigate whether
post-transcriptional, rather than transcriptional, regulatory
events could be the key factor explaining the broad
anti-inflammatory effects of ITF2357. Of note, recent
reports indicate that prolonged exposure to TNF leads to
a gradual reshaping of the FLS transcriptome, which is
largely dependent on mRNA stability processes [14],
highlighting the importance of post-transcriptional regula-
tory mechanisms in maintaining the chronicity of inflam-
mation in RA. We extended our analysis to additional
IL-1β-induced cytokines (IL8, CXCL2) and mediators of
inflammatory responses, matrix degradation, and cell sur-
vival (PTGS2, ADAMTS1, and BCL2L1). We confirmed
that a subset of these genes, specifically IL8, CXCL2 and
PTGS2, were subject to mRNA stability regulation by
ITF2357. On the contrary, some targets displayed
sustained stability (MMP1–3, CXCL10, CXCL5–6), while
others rapidly decayed over time but were not further
destabilized by ITF2357 (IRF1, FoxO1). More intriguingly,
kinetics played an important role in the transcriptional or
post-transcriptional regulation of genes affected by
ITF2357. Indeed, while mostly affected at the transcriptional
level after shorter exposure to ITF2357, the mRNA expres-
sion of IL6, IL8 and PTGS2 was post-transcriptionally
regulated at later time points. These results indicate that the
initial anti-inflammatory events mediated by ITF2357 occur
by suppressing the nascent production of cytokine mRNA,
while subsequent immune suppressive functions are related
to the destabilization of their transcripts.
A key mechanism responsible for the post-transcriptional
regulation of gene expression is ARE-BP-mediated mRNA
decay [4]. We evaluated whether ARE-BP could mediate
the effects of ITF2357 on cytokine mRNA stability in RA
FLS and found that TTP mRNA expression rapidly
increased after short exposure to IL-1β. After treatment
with ITF2357, TTP mRNA was not stabilized despite being
induced at all time-points, implying that a transcriptional
component is responsible for the regulation of this ARE-BP
by HDACi. To date, the mRNA-destabilizing TTP has been
best described as a regulator of inflammatory processes
[40]. TTP expression is significantly increased in the
synovial joints in RA compared to non-inflamed joints, and
it is abundant in macrophages and synovial fibroblasts [41],
possibly indicating a relevant role for this ARE-BP in these
cells. Studies of peripheral blood mononuclear cells in RA
have reported a global reduction of TTP expression,
compared to healthy controls and patients with osteoarth-
ritis (OA) [12, 42]. In animal studies, knockout of TTP has
been shown as sufficient to the development of a complex
inflammatory phenotype, characterized by auto-immunity
and polyarthritis [10] On the contrary, induction of TTP
expression is protective in collagen-induced arthritis
(CIA) [13].
In our study, we observed that besides affecting the
transcriptional regulation of TTP, ITF2357 additionally
reduced the abundance of a higher molecular-weight
form of TTP. Treatment with phosphatase confirmed
this as the phosphorylated form of the protein. The
destabilizing effects of ITF2357 on TTP mRNA decay
further support this finding, as dephosphorylated and
active TTP would also cause its own mRNA to be
degraded [13]. The equilibrium between the phosphory-
lated and the dephosphorylated pools of TTP has
frequently been reported to be a critical feature in the
determination of the inflammatory response [30]. Mice
expressing a phosphorylation-deficient form of TTP, in
which serines 52 and178 are converted to arginine
residues, are protected from CIA, as a consequence of
increased functionality of the protein [11, 30]. Also,
activation or depletion of phosphatases that revert TTP
to its dephosphorylated form, such as PP2A and Dusp1,
reduce the production of cytokines such as IL6, IL8 and
TNF, and increase broad pro-inflammatory gene expres-
sion, respectively [11, 43, 44].
Phosphorylation is the most common post-translational
modification of TTP and other ARE-BP, but other modifi-
cations have been reported [45, 46]. Thus, it remains
possible that ITF2357 may enhance the acetylation levels
of TTP and subsequently reduce its phosphorylation.
Indirect regulation of TTP phosphorylation by HDACi is
(See figure on previous page.)
Fig. 2 ITF2357 accelerates the mRNA decay of inflammatory markers. a Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) (n = 6) were left
untreated or were treated with ITF2357 prior to incubation with IL-1β for 2 h. Transcription was blocked with actinomycin D (ActD) and RNA
extracted at the indicated time points. Graphs show representative genes with enhanced mRNA degradation in the presence of ITF2357 (top
panel), and examples of genes that were not regulated by ITF2357 at the level of transcript stability (bottom panel): *p < 0.05, Wilcoxon matched
pairs test. b RA FLS (n = 7) were left untreated or were treated with ITF2357 prior to incubation with IL-1β for 4 and 8 h. The expression of
primary transcripts (PT) and mature transcripts of IL6, IL8, PTGS2 and MMP1 were assessed by qPCR. Results are presented as 2^(-ΔCT) of the targets
of interest normalized to GAPDH housekeeping gene. Percentages indicate the average suppression caused by the presence of ITF2357 in the 7
independent experiments: *p < 0.05, **p < 0.01, ***p < 0.001, one-way analysis of variance with Greenhouse-Geisser correction followed by Fisher’s
least significant difference test
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Fig. 3 Tristetraprolin (TTP) expression and activity are induced by ITF2357. a, b Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) were
left untreated or were treated with ITF2357 before incubation with IL-1β for either 2 h (a, n = 4) or for 4 and 8 h (b, n = 6). The mRNA expression
of the Adenosine uridine-rich elements (ARE) binding proteins (ARE-BP) was analyzed by qPCR. c RA FLS (n = 6) were subject to mRNA stability
analysis as specified in Fig. 2a and TTP expression was analyzed by qPCR: *p < 0.05, Wilcoxon matched pairs test. d RA FLS (n = 4) were treated
with ITF2357 before incubation with IL-1β for either 2 h, 4 h or 8 h and the expression levels of TTP primary and mature transcript were analyzed
by qPCR. Graph shows the 2^(-ΔCT) ratio of the primary/mature transcript normalized to GAPDH housekeeping gene. e RA FLS were left untreated
or were treated with ITF2357 before incubation with IL-1β for 2 and 4 h. Protein lysates were processed for immunoblotting with antibodies
recognizing TTP and tubulin (left panel) and signal intensity (n = 8) was subsequently quantified by densitometry analysis (right panel). Band with
higher apparent molecular mass corresponds to the post-translationally modified protein. d, e *p < 0.05, **p < 0.01, one-way analysis of variance
with Greenhouse-Geisser correction followed by Fisher’s least significant difference test. ActD, actinomycin D; AUF, AU-rich binding factor; KHSRP,
KH-type splicing regulatory protein; HuR, Hu antigen R
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ab
Fig. 4 Knockdown of adenosine uridine-rich elements binding proteins does not cause changes in the expression of inflammatory mediators.
a Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) (n = 3) were left untransfected or were transfected for 72 h with 20 nM control
non-targeting siRNA (siCtrl) or 20 nM specific siRNA targeting AUF1 (siAUF1), BRF1 (siBRF1), BRF2 (siBRF2), KHSRP (siKHSRP) and HuR (siHuR).
Knockdown efficiency was verified at the mRNA level by qPCR. Data are presented as fold expression of mRNA compared to siCtrl transfected
cells:*p < 0.05, **p < 0.01, ratio t test. b RA FLS (n = 3) were transfected as in a and further left untreated or treated with ITF2357, prior to
stimulation with IL-1β for 8 h. IL6, IL8, CXCL2 and PTGS2 expression were determined by qPCR. Data are presented as fold expression of mRNA
compared to siCtrl-treated IL-1β stimulated cells: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way analysis of variance followed by
Fisher’s least significant difference test
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yet another possibility. In fact, evidence from the literature
suggests that HDAC1,2 and 3 can bind to and acetylate
Dusp1 [47]. On the contrary, direct effects of HDACi on
p38 activation are likely to be excluded, as we found
pan-HDACi to leave p38 phosphorylation unaltered in
IL-1β-stimulated FLS [22]. Similarly, ITF2357 may affect
mRNA stability independently of the c-Jun N-terminal
kinase (JNK) signaling pathway, as FoxO1 mRNA stability,
previously shown to be mediated by JNK inhibition [48]
was not affected by ITF2357.
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Fig. 5 Tristetraprolin (TTP) silencing in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) and murine fibroblasts induces cytokine
expression. a RA FLS (n = 4) were left untransfected or were transfected with control non-targeting siRNA (siCtrl) or specific siRNA targeting TTP
(siTTP). Knockdown efficiency was verified at the mRNA level by qPCR (left panel) and by immunoblotting (right panel). For immunoblot samples,
cells were stimulated with IL-1β for 2 h. Protein lysate was analyzed with antibodies recognizing TTP or control H3: **p < 0.01, ratio t-test. b RA
FLS (n = 7) were transfected as in a, and further left untreated or treated with ITF2357, prior to stimulation with IL-1β for 8 h. Gene expression
was determined by qPCR. Data are presented as fold change in mRNA expression compared to siCtrl conditions. c RA FLS were processed as in
b, IL6, IL8, CXCL2 and PTGS2 (n = 7) and TTP expression (n = 3) was determined by qPCR. Data presented as fold change in mRNA expression
compared to siCtrl-IL-1β stimulated conditions. d Wild-type (ZFP36+/+) or TTP knockout (ZFP36−/−) murine fibroblasts (n = 4) were either left
untreated or treated with ITF2357 and were further stimulated with IL-1β. Gene expression was determined by qPCR. Results are presented as 2^(-
ΔCT)× 100 of the target of interest normalized to ACTB housekeeping gene. b-d *p < 0.05, **p < 0.01, one-way analysis of variance with
Greenhouse-Geisser correction followed by Fisher’s least significant difference test
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We tested whether single silencing of multiple ARE-BP
could result in the differential regulation of IL6, IL8,
CXCL2 and PTGS2. Unlike other ARE-BP, TTP silencing
caused increased expression of inflammatory mediators
and proved to be a critical regulatory factor in RA FLS.
Additionally, ITF2357 reduced IL6 and CXCL2 production
in ZFP36+/+ but not ZFP36−/− murine fibroblasts, overall
demonstrating crucial involvement of TTP in IL6 regula-
tion by HDACi.
Conclusions
Recent studies suggested that the induced expression and
the reduced phosphorylation of TTP could be beneficial
in dampening inflammatory responses in arthritis [11].
Our results indicate that ITF2357 functions as an activator
of TTP function and transcription in RA FLS, and provide
novel understanding of how HDACi dictate not only the
transcriptional, but also the post-transcriptional regulation
of inflammatory genes. These findings provide rationale
for further evaluation of HDACi as a therapeutic tool in
RA and other chronic inflammatory diseases.
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